Predictors of Cardiac Recovery in Adults With AML Who Develop Heart Failure During Treatment
Our retrospective single-center analysis suggests that approximately half of the patients with AML who experience LVEF decline during induction will not recover. Ischemic events during treatment were predictive of nonrecovery. The use of GDMT may improve prognosis for some patients. Given the impact of recovery, we propose the prospective verification and establishment of cardiac management algorithms in patients with AML.
Authors
- Paul C. Hendrie (ORCID: https://orcid.org/0000-0003-1902-5972)
- Roland B. Walter (ORCID: https://orcid.org/0000-0002-9268-3341)
- Jacob Appelbaum (ORCID: https://orcid.org/0000-0002-4362-7773)
- Kathryn Russell (ORCID: https://orcid.org/0009-0003-2503-4207)
- Matthew A. Wu (ORCID: https://orcid.org/0000-0002-7099-2290)
- Cristina Maria Ghiuzeli
- Mary‐Elizabeth M. Percival (ORCID: https://orcid.org/0000-0002-7016-951X)
- Anna B. Halpern (ORCID: https://orcid.org/0000-0002-4326-0748)
- Carole Shaw
Institutions
- University of Washington (US)
- University of Washington Medical Center (US)
- Fred Hutch Cancer Center (US)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1200/op-24-00734
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00